ThermoGenesis Corp. to Present at 2007 Global Life Sciences Conference on Thursday, September 27, 2007
RANCHO CORDOVA, Calif., Sept. 19 / -- ThermoGenesis Corp. a leading supplier of innovative products and services that harvest, process, store, and administer therapeutic doses of adult stem cells for trea(TM)ent of disease and injury, announced today that Dr. William Osgood, the Company's Chief Executive Officer, and Mr. Matthew Plavan, Chief Financial Officer, will participate in the 2007 Global Life Sciences Conference to be held September 24 through September 27, 2007 at the Grand Hyatt in New York City. Dr. Osgood is scheduled to present an overview of the Company's business activities, at 1:30PM Eastern time on Thursday, September 27, 2007.
To listen to the audio web cast of the presentation during or after the event, please visit: http://www.thermogenesis.com/investor_relations/index.asp.
The replay of the presentation will also be accessible for 30 days after the conference.
About ThermoGenesis Corp.
ThermoGenesis Corp. (http://www.thermogenesis.com/) is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These products include:
o The BioArchive® System, an automated cryogenic device, is used by
cord blood stem cell banks in more than 25 countries for cryopreserving
and archiving cord blood stem cell units for transplant. GE Healthcare
is the non-exclusive global distribution partner for the BioArchive
System.
o AXP(TM) AutoXpress Platform (AXP(TM)) is a proprietary, semi-automated
device and companion sterile blood processing disposable for harvesting
stem cells from cord blood in a functionally closed system. GE
Healthcare is the exclusive global distribution partner for the AXP
AutoXpress Platform.
o The CryoSeal® FS System, an automated device and companion sterile
blood processing disposable, is used to prepare fibrin sealants from
plasma in about an hour. We received FDA clearance to market the
CryoSeal FS System in liver resection surgeries in July 2007. The
CryoSeal FS System has received the CE-Mark. From a marketing
perspective, the CE Mark is the European equivalent to an FDA approval,
in that it allows sales of the product throughout the European
community. Asahi Medical is the exclusive distributor for the CryoSeal
System in Japan and the Company markets through independent
distributors in Europe and South America.
o The Thrombin Processing Device(TM)(TPD(TM)) is a sterile blood
processing disposable that prepares activated thrombin from a small
aliquot of plasma in less than 30 minutes. The CE-Marked TPD is
currently being marketed in Europe by Biomet, Inc., subsidiary Biomet
Biologics, Medtronic, Inc. and independent distributors.
FCMN Contact: epoutre@thermogenesis.com
Source: ThermoGenesis Corp.
CONTACT: Matthew T. Plavan, +1-916-858-5100, or Ryan Rauch,
+1-760-586-8699, both of ThermoGenesis Corp.
Web site: http://www.thermogenesis.com/
